Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s obesity drug Zepbound lost nearly 50% more weight than those using rival Novo ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Poison control experts say calls related to GLP-1 weight-loss drugs like Wegovy and Zepbound are rising, with symptoms like ...

Microdosing isn’t just popular for psychedelics. Some consumers are taking smaller than standard doses of GLP-1s—the popular ...